Acumen Pharmaceuticals Inc

NASDAQ ABOS

Download Data

Acumen Pharmaceuticals Inc Net Debt to EBITDA Ratio 5 year CAGR for the year ending December 31, 2023

Acumen Pharmaceuticals Inc Net Debt to EBITDA Ratio 5 year CAGR is NA for the year ending December 31, 2023. The net debt to EBITDA ratio measures the level of a company's net debt relative to its earnings before interest, taxes, depreciation, and amortization (EBITDA). It is calculated by dividing the net debt (total debt minus cash and cash equivalents) by EBITDA. This ratio provides insights into the company's ability to repay its debt using its operating earnings. A higher ratio indicates a higher level of debt relative to earnings, suggesting potential financial risk and difficulty in debt repayment. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Acumen Pharmaceuticals Inc Net Debt to EBITDA Ratio for the year ending December 31, 2022 was 2.88, a 245.39% change year over year.
  • Acumen Pharmaceuticals Inc Net Debt to EBITDA Ratio for the year ending December 31, 2021 was -1.98, a -138.51% change year over year.
  • Acumen Pharmaceuticals Inc Net Debt to EBITDA Ratio for the year ending December 31, 2020 was 5.15, a 502.10% change year over year.
  • Acumen Pharmaceuticals Inc Net Debt to EBITDA Ratio for the year ending December 31, 2019 was 0.86.
NASDAQ: ABOS

Acumen Pharmaceuticals Inc

CEO Mr. Daniel J. O'Connell M.B.A.
IPO Date July 1, 2021
Location United States
Headquarters 427 Park Street, Charlottesville, VA, United States, 22902
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email